| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 06/26/2008 | WO2008076815A2 Pro-angiogenic peptides |
| 06/26/2008 | WO2008076788A2 Optimized pan-her ligands |
| 06/26/2008 | WO2008076784A2 Methods and compositions for treating il-4 or il-13 related fibrosis related pathologies |
| 06/26/2008 | WO2008076454A1 Immunogenic compositions comprising progastrin and uses thereof |
| 06/26/2008 | WO2008076437A2 Activin-actrii antagonists and uses for increasing red blood cell levels |
| 06/26/2008 | WO2008076370A2 P21 compositions and methods for the treatment of hiv |
| 06/26/2008 | WO2008076275A2 Inhibiting collagen-induced platelet aggregation and activation with peptide variants |
| 06/26/2008 | WO2008076003A1 Composition of individual proteolytic enzymes |
| 06/26/2008 | WO2008075957A1 Treatment of fabry disease |
| 06/26/2008 | WO2008075796A1 Agent for promoting recovery from blood cell depletion |
| 06/26/2008 | WO2008075706A1 Therapeutic agent for interstitial pneumonia |
| 06/26/2008 | WO2008075684A1 Antibiotic glycopeptide derivative |
| 06/26/2008 | WO2008075379A1 Novel formulation for enhanced delivery of diagnostic agents to tumor tissues |
| 06/26/2008 | WO2008075370A2 T-140 peptide analogs having cxcr4 super-agonist activity for cancer therapy |
| 06/26/2008 | WO2008075369A2 T-140 peptide analogs having cxcr4 super-agonist activity for bone marrow recovery |
| 06/26/2008 | WO2008075365A1 Compositions and methods for treatment of age related degeneration of the retina |
| 06/26/2008 | WO2008075363A1 Variants of vegfr and their use in the diagnosis and treatment of pregnancy associated medical conditions |
| 06/26/2008 | WO2008075349A1 Therapeutic methods using a thymus peptide |
| 06/26/2008 | WO2008075333A2 Edible compositions for preventing hair loss |
| 06/26/2008 | WO2008074885A2 Process for manufacturing ophthalmic oil-in-water emulsions |
| 06/26/2008 | WO2008074868A1 Oral delivery of polypeptides |
| 06/26/2008 | WO2008074865A1 Dimeric prolactin receptor ligands |
| 06/26/2008 | WO2008074813A2 Optiogenin for the treatment of neural diseases |
| 06/26/2008 | WO2008074424A2 Coding genes with a single exon for new bioactive peptides |
| 06/26/2008 | WO2008074230A1 Interferon alpha mutant and its polyethylene glycol derivative |
| 06/26/2008 | WO2008074128A1 Pharmaceutically acceptable salts of thymodepressin and processes for their manufacture |
| 06/26/2008 | WO2008057313A9 Methods of using e2f2 for the treatment of hypertension |
| 06/26/2008 | WO2008054695A3 Composition and method for etiological treatment and prevention of diseases and/or complications associated with chronic glucose metabolism destabilization |
| 06/26/2008 | WO2008054585A3 Use of pegylated il-10 to treat cancer |
| 06/26/2008 | WO2008050363A3 Use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of autoimmune diseases |
| 06/26/2008 | WO2008048121A3 Macrocyclic cysteine protease inhibitors and compositions thereof |
| 06/26/2008 | WO2008046228A8 Compounds for stimulating p-glycoprotein function and uses thereof |
| 06/26/2008 | WO2008045345A3 Method of treating or preventing tissue deterioration, injury or damage due to periodontal disease or disease of oral mucosa, and/or downregulating nf-kappab or suppressing nf-kappab-mediated actions |
| 06/26/2008 | WO2008036387A8 Method of treating endothelial dysfunction |
| 06/26/2008 | WO2008035243A3 Composition for treatment of burns and wounds |
| 06/26/2008 | WO2008030260A3 Treatment of variola viral infections using a tissue factor inhibitor |
| 06/26/2008 | WO2008019394A3 Methods for treatment and diagnosis of psychiatric disorders |
| 06/26/2008 | WO2008013938A3 Aerosolizable formulation comprising insulin for pulmonary delivery |
| 06/26/2008 | WO2008009639A3 New indications for direct thrombin inhibitors |
| 06/26/2008 | WO2007143957B1 'transfer factor' medicament - ways of manufacturing and use |
| 06/26/2008 | WO2007123847A3 Treatment of melanoma |
| 06/26/2008 | WO2007104541A3 Compositions and methods using serine protease inhibiting peptides for treating ophthalmic disorders |
| 06/26/2008 | WO2007101676A3 Treatment, diagnosis and imaging of mantle cell lymphoma |
| 06/26/2008 | WO2007101005A3 Compositions and methods for effecting controlled posterior vitreous detachment |
| 06/26/2008 | WO2007068736A3 New chemokine antagonists |
| 06/26/2008 | WO2007013807A9 Targeting-enhanced activation of galectins |
| 06/26/2008 | WO2006127514A3 Compositions and methods for treating hiv infection with cupredoxin and cytochrome c |
| 06/26/2008 | WO2006026570A8 Use of stem cells to generate inner ear cells |
| 06/26/2008 | WO2005076981A3 Methods and compositions related to neuronal differentiation |
| 06/26/2008 | US20080155703 Identifying new immunomodulatory chemical entities (NICE); reacting a candidate NICE with a Tat SH3 binding domain, identifying the bound candidate NICE and determining whether it induces monocytes to differentiate into dendritic cells (DC) or regulatory macrophages (AReg); drug screening; immunotherapy |
| 06/26/2008 | US20080154210 Mixture for Transdermal Delivery of Low and High Molecular Weight Compounds |
| 06/26/2008 | US20080154022 Transport of basic fibroblast growth factor across the blood brain barrier |
| 06/26/2008 | US20080153921 Amphipathic, lipophilic anti-oxidants, made into potent abzyme inhibitors by increasing solubility in aqueous solvents with lactoproteins; test solublized carotenoids, polyphenols, flavonoids, isoflavones, curcuminoids, ceramides to identify, obtain a composition which inhibits lipid oxidising abzymes |
| 06/26/2008 | US20080153913 Nutritional Supplement and Protocol |
| 06/26/2008 | US20080153768 Treatment of neurological disorders by dsrna administration |
| 06/26/2008 | US20080153767 Modulation of forkhead box o1a expression |
| 06/26/2008 | US20080153766 Non-insulin dependent diabetes mellitus; lowers hepatic fatty degeneration; improving liver function by reducing alanine transaminase and aspartate transaminase levels |
| 06/26/2008 | US20080153759 Treatment methods using polypeptides related to amyloid precursor protein |
| 06/26/2008 | US20080153758 6-[Amino(4-chlorophenyl)-1-methyl-1H-imidazol-5-ylmethyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2R)-2-Amino-3-mercaptopropyl]amino]-3-methylpentyl]oxy]-1-oxo-3-phenylpropyl]amino]-4-(methylsulfonyl)-butanoic acid 1-methylethyl ester; exhibit potent activity agains |
| 06/26/2008 | US20080153757 Contains ascorbic acid, phenylalanine or tyrosine, ethyl lactate and a non-toxic zinc salt (zinc sulfate) |
| 06/26/2008 | US20080153756 Nucleic acids encoding them; for use in modulating alpha 4 integrin function; kits; antibodies against the peptides |
| 06/26/2008 | US20080153755 Antitumor peptide; risk of adverse immune reactions such as anaphylactic shock is greatly diminished |
| 06/26/2008 | US20080153754 Phenotypic reversion of pancreatic carcinoma cells |
| 06/26/2008 | US20080153753 Method of treating side effects induced by therapeutic agents |
| 06/26/2008 | US20080153752 artificial polypeptides as inhibitor of hyaluronic acid, chondroitin sulfate A, chondroitin sulfate C, dermatan sulfate, heparin, keratan sulfate, keratosulfate, chitin, chitosan 1, and chitosan 2; for treatment of inflammatory diseases, tumor, cancer, cancer metastasis, and autoimmune diseases |
| 06/26/2008 | US20080153751 Albumin Fusion Proteins |
| 06/26/2008 | US20080153750 Fermenting an appropriate microorganism using glucose as a carbon source and separating by chromatography, has a purity of at least 98%; specific binding or targeting to transferrin; use in the treatment of CNS neoplasm; antitumor agents |
| 06/26/2008 | US20080153749 Methods and compositions for cell-cycle regulation |
| 06/26/2008 | US20080153748 Antimicrobial polypeptides; topical applying a fungicide biodrug for treating nail infections and athlete's foot |
| 06/26/2008 | US20080153747 taipan natriuretic peptide is used for treating congestive heart failure, stimulating vasodilation, natriuresis, diuresis, renin-suppression, bactericidal activity, weight-loss or bone growth; antigen-binding molecule |
| 06/26/2008 | US20080153746 Diagnosis and Treatment of Myeloid and Lymphoid Cell Cancers |
| 06/26/2008 | US20080153745 Compositions of tRNA and uses thereof |
| 06/26/2008 | US20080153744 Novel cyclosporin alkynes and their utility as pharmaceutical agents |
| 06/26/2008 | US20080153743 Methods relating to the treatment of fibrosis |
| 06/26/2008 | US20080153742 Fas peptide mimetics and uses thereof |
| 06/26/2008 | US20080153741 mixture of small molecular weight nucleoprotein, deoxyoligonucleotide, DNA or RNA enzymatic or hydrolytic degradation product; obtained from fishes, yeast; easy transdermal absorption, improve hydrophilic, sebum level balance, preventing wrinkles; aging resistance |
| 06/26/2008 | US20080153740 Methods for increasing protein polyethylene glycol (PEG) conjugation |
| 06/26/2008 | US20080153739 Compositions and methods for treatment of hyperplasia |
| 06/26/2008 | US20080153738 Compositions and methods for treatment of hyperplasia |
| 06/26/2008 | US20080153737 Method of Delivering Rna Interference and Uses Thereof |
| 06/26/2008 | US20080153159 Therapeutic and diagnostic agents |
| 06/26/2008 | US20080153131 Free of transmembrane domain; immunoglobulins; autoimmune diseases |
| 06/26/2008 | US20080153112 identification of a predominant ligand of CD8+ T cells that are responsible eq for type 1 diabetes. That ligand is islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP). Several CD8+ T cell-binding peptides from IGRP are identified, including the peptide comprising amino acids |
| 06/26/2008 | US20080153104 Gene Overexpressed in Cancer |
| 06/26/2008 | US20080152720 Nanoparticulate tacrolimus formulations |
| 06/26/2008 | US20080152707 Solubilized CoQ-10 and Carnitine |
| 06/26/2008 | US20080152706 Wherein the dihydrolipoic acid acts as a reducing agent for the coenzyme Q10 and also, optionally, as a solvent; periodontal diseases, mitochondrial related diseases and disorders, Parkinson's disease, Prader-Willi syndrome, migraines |
| 06/26/2008 | US20080152702 Improved blood circulation lifetime of drug-carrying liposomes having a surface coating of releasable hydrophilic polymer covalently and reversibly linked to an phospholipid or polypeptide through a dithiobenzyl linkage |
| 06/26/2008 | US20080152701 Methods and Compositions for the Treatment and Prevention of Staphylococcus Infections |
| 06/26/2008 | US20080152696 Nutritional supplement for children from infants to adolescents; tablets, capsules or reconstitutable powders containing partially hydrolyzed recombinant leptin |
| 06/26/2008 | US20080152690 Biodegradable, anionic polymers derived from the amino acid l-tyrosine |
| 06/26/2008 | US20080152689 Devices containing dna encoding neurotrophic agents and related compositions and methods |
| 06/26/2008 | US20080152668 Thymosin Alpha 1 Peptide/Polymer Conjugates |
| 06/26/2008 | US20080152666 Apoptosis-inducing polypeptides |
| 06/26/2008 | US20080152665 Therapy of cancer based on targeting adaptive, innate and/or regulatory component of the immune response |
| 06/26/2008 | US20080152661 Polyconjugates for In Vivo Delivery of Polynucleotides |
| 06/26/2008 | US20080152660 Anti-Angiogenic Compounds |
| 06/26/2008 | US20080152659 Using presence of deletion in complement Factor H-related 4 gene as evaluative tool in predicting aneurysm and vision defects |
| 06/26/2008 | US20080152656 Using kallikren specific inhibitor as therapeutic tool in treating cardiocascular disorders; treating soft tissue and bone trauma; tissue repair |
| 06/26/2008 | US20080152652 Stem cell factor specific immunoglobulin for use in prevention and treatment of blood disorders |